Coya Therapeutics, Inc. COYA
5.08
(0.10)
(1.93%)
as of 25 Sep
- Market cap
- $121.5M
- P/E
- 0.0×
Follow COYA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | — |
P/S ratio |
12.21 | 0.00 | 0.00 | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | — | — |
P/Operating CF |
(96.35) | (36.24) | (31.57) | — | — | — |
P/B ratio |
2.26 | 2.21 | 1.99 | — | — | — |
Price to Tangible BV |
2.26 | 2.21 | 1.99 | — | — | — |
EV/Sales |
7.95 | 0.00 | 0.00 | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
(5.88) | (6.02) | (4.57) | — | — | — |
EV/FCF |
(5.31) | (6.01) | (4.21) | — | — | — |
Quick Ratio |
7.97 | 10.02 | 7.94 | 1.55 | 3.78 | 19.51 |
Current Ratio |
8.50 | 11.59 | 8.15 | 1.88 | 3.99 | 19.57 |
Net Debt/EBITDA |
2.08 | 2.23 | 4.14 | (0.72) | 0.89 | 12.55 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 154.43% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | (1.54) | 0.00 | 0.00 |
Asset Turnover |
0.17 | 0.08 | 0.24 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.51 | 0.69 | 1.40 | 0.59 | 0.80 | 0.53 |
Capex/Depreciation |
(42.50) | (0.91) | (19.82) | (19.16) | (8.50) | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (51.39%) | (39.57%) | (86.60%) | 109.64% | 173.42% | 0.00% | |
| (45.02%) | (34.76%) | (32.17%) | (185.70%) | (72.25%) | 0.00% | |
ROIC |
0.00% | (871.34%) | (164.17%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(48.16%) | (36.72%) | (22.06%) | (354.44%) | (137.54%) | (8.83%) |
Average Days of Receivables |
0.00 | 0.00 | 456.08 | — | — | 0.00 |
Research and Development Expense of Revenue |
210.61% | 333.86% | 91.66% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
144.09% | 250.02% | 130.51% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
53.99% | 74.94% | 14.53% | 0.00% | 0.00% | — |
Graham Net Nets |
0.44 | 0.45 | 0.50 | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
(21.90%) | (17.10%) | (11.21%) | — | — | — |
Free Cash Flow Yield |
(12.27%) | (11.81%) | (17.14%) | — | — | — |
Revenue per Share |
0.47 | 0.23 | 0.59 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.64) | (0.68) | (1.10) | (2.79) | (1.51) | (0.04) |
Capex per Share |
(0.07) | 0.00 | (0.05) | (0.20) | (0.05) | 0.00 |
Free Cash Flow per Share |
(0.71) | (0.68) | (1.15) | (3.00) | (1.56) | (0.04) |
Cash per Share |
2.80 | 2.52 | 3.21 | 2.29 | 1.68 | 0.90 |
Shareholders Equity per Share |
2.57 | 2.60 | 3.51 | (3.24) | 1.41 | 0.86 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.57 | 2.60 | 3.51 | (3.24) | 1.41 | 0.86 |
Free Cash Flow |
(11.90) | (10.31) | (11.73) | (7.76) | (4.04) | (0.39) |
Working Capital |
44.07 | 40.48 | 36.14 | 3.36 | 3.44 | 8.30 |
Capital Expenditures |
(1.16) | (0.02) | (0.54) | (0.52) | (0.14) | — |
Net Current Asset Value |
43.02 | 39.54 | 35.57 | (9.60) | 3.44 | 8.30 |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
0.15 | 0.01 | 0.09 | 0.00 | 0.00 | — |
Net Profit Margin |
(267.14%) | (418.69%) | (133.08%) | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||
Depreciation/Fixed assets |
2.45 | 0.71 | 0.42 | 0.29 | 0.13 | — |
Cash ROIC |
(11.96%) | (13.25%) | (16.49%) | (69.80%) | (50.40%) | (2.30%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 1.60 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — |
Average Receivables |
— | — | 3.75 | — | — | — |
Average Payables |
1.32 | 1.37 | 1.49 | 1.34 | 0.65 | — |
Average Assets |
47.15 | 42.80 | 24.83 | 6.59 | 6.77 | — |
Average Common Equity |
41.30 | 37.61 | 9.22 | (11.17) | (2.82) | — |
Columns are period end dates